Physical Therapists in Leawood, KS Accepting Medicare
85 Physical Therapists found. Showing 81 - 85
 Dr. Hannah Wessel, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 12728 State Line Rd, Leawood, KS 66209 Phone: 913-888-0014 |
Mrs. Kayla Anne Powers, PT, DPT, MLD-C Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3715 W 133rd St, Leawood, KS 66209 Phone: 913-213-3531 |
Taylor Marie Neilson, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 12728 State Line Rd, Leawood, KS 66209 Phone: 913-888-0014 |
Megan Elle Algya, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 12728 State Line Rd, Leawood, KS 66209 Phone: 913-888-0014 |
Larissa L Michaelis, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 8610 Meadow Ln, Leawood, KS 66206 Phone: 816-217-4406 |
News Archive
Reducing SSB intake among children and adolescents associated with greater increase in HDL-C
In the first study to investigate blood lipid levels in association with consumption of sugar-sweetened beverages (SSBs) in a racially and ethnically diverse sample of Boston area schoolchildren, researchers found there was an inverse association between SSB intake changes and HDL-cholesterol increases (HDL-C is the "good cholesterol").
Spirituality associated with poor mental health
Individuals who describe themselves as spiritual are more likely to have used drugs, or be dependent on drugs, and also more likely to have generalized anxiety and neurotic disorders than those who are neither spiritual nor religious, research shows.
OUHSC gets $20 million grant to advance research and patient care for Oklahomans
This week, the University of Oklahoma Health Sciences Center announced the nationally competitive renewal of a $20 million federal grant that will advance research and patient care for Oklahomans throughout the state.
FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Regulators miss deadline on medical loss ratios: Other implementation developments continue to emerge
Insurance regulators have missed an early deadline to set specific rules meant to ensure that insurers devote 80 to 85 percent of premium dollars to medical care, the so-called "medical loss ratio."
› Verified 1 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists
Chiropractors
Optometrists
Podiatrists